Call for Abstract

3rd Antibodies and Bio Therapeutics Congress, will be organized around the theme “Global Update on Antibodies, Bio Therapeutics: Research, Development and Market”

Antibodies-2017 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Antibodies-2017

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

An autoantibody is an antibody (a type of protein) produced by the immune system that is directed against one or more of the individual's own proteins. Normally, the immune system is able to recognize and ignore the body's own healthy proteins, cells, and tissues, and to not overreact to non-threatening substances in the environment, such as foods. The immune system ceases to recognize one or more of the body's normal constituents as "self," leading to production of pathological auto antibodies. These auto antibodies attack the body's own healthy cells, tissues, and/or organs, causing inflammation and damage. Autoantibody tests may be ordered as part of an investigation of chronic progressive arthritis type symptoms and/or unexplained fevers, fatigue, muscle weakness and rashes. The Antinuclear antibody (ANA) test is often ordered first. ANA is a marker of the autoimmune process – it is positive with a variety of different autoimmune diseases but not specific. Antibody Profiling is used for identifying persons from forensic samples. The technology can uniquely identify a person by analyzing the antibodies in body fluids.

Antibody engineering is a great tool for improving antibody functions and immunogenicity improvement. Engineered therapeutic antibodies are better for affinity maturation, specifically by improving on-rate of the antibody binding affinities. The need to overcome the immunogenicity problem of rodent antibodies in clinical practise has resulted in a plethora of strategies to isolate human antibodies.

  • Track 2-1Antibody Biosynthesis, Structure and Stability
  • Track 2-2Bi-Specific Antibody Engineering
  • Track 2-3New Ways to Extend the in vivo Half-Life of Antibodies
  • Track 2-4Fc Engineered Antibodies and Special Antibody Engineering
  • Track 2-5Unique Therapeutic Vistas in Antibody Engineering: Bispecifics
  • Track 2-6Antibodies in a Complex Environment

The evidence indicates that two simian immunodeficiency viruses (SIV), one from Chimpanzees (SIVcpz) and the other from sooty mangabeys (SIVsm), crossed the species barrier to humans, generating HIV-1 and HIV-2, respectively. The importance of characterizing the prevalence, geographic distribution, and genetic diversity of naturally occurring SIV infections to investigate whether humans continue to be exposed to SIV and if such exposure could lead to additional zoonotic transmissions. Through vigorous efforts made in the past two centuries, public health workers have succeeded in developing vaccines, antibiotics, and chemotherapeutics, and as a result most infectious diseases have been brought under control in industrialized countries. However, in developing countries, infectious diseases have been harder to contain, and the increase in migration and movement of populations in the last two decades has made national boundaries disappear as far as the transmission of infection is concerned. Some diseases, such as malaria, have been eradicated from industrialized countries mainly through extensive work on vector control, but their presence in developing countries has increased because of neglect or drug resistance. One of these proteases (Histidine Aspartic Protease, HAP) is homologous to three other aspartic proteases involved in hemoglobin metabolism but has a histidine in place of one of the two aspartic acids involved in catalysis.
 

  • Track 3-1The Growing Challenge of Antibiotic Resistance
  • Track 3-2Antibodies for Pediatrics Diseases
  • Track 3-3Therapeutic Antibodies for Neurological Disease and other Neglected Diseases
  • Track 3-4Novel Therapeutic Antibodies for Infectious and Inflammatory Diseases
  • Track 3-5Novel Therapeutic Antibodies for Allergy, Asthma and Autoimmune Diseases

Auto-antibody is an antibody formed in response to, and reacting against, an antigenic constituent of the individual's own tissues. Several mechanisms may trigger the production of autoantibodies: an antigen, formed during fetal development and then sequestered, may be released as a result of infection, chemical exposure or trauma, as occurs in autoimmune thyroiditis, sympathetic uveitis and aspermia; there may be disorders of immune regulatory or surveillance function.      
 

  • Track 4-1Remarkable Findings of Auto-antibodies: Testing and Treatment
  • Track 4-2Antibody Fingerprinting: A Novel Method for Identifying Individual People and Animals
  • Track 4-3Current insights into the" antiphospholipid" syndrome: clinical, immunological, and molecular aspects
  • Track 4-4Autoantibodies in infertility: current opinion
  • Track 4-5The origin and pathogenic role of anti-DNA autoantibodies

Monoclonal antibody therapy is a process in which monoclonal antibodies (mAb) are used to bind monospecifically to certain cells or proteins. This may then stimulate the patient's immune system to attack those cells. Alternatively, in radioimmunotherapy a radioactive dose localizes on a target cell line, delivering lethal chemical doses. More recently antibodies have been used to bind to molecules involved in T-cell regulation to remove inhibitory pathways that block T-cell responses, known as immune checkpoint therapy. It is possible to create a mAb specific to almost any extracellular/ cell surface target. Research and development is underway to create antibodies for diseases (such as rheumatoid arthritis, multiple sclerosis, Alzheimer's disease, Ebola and different types of cancers).     

  • Track 5-1Advantages in Monoclonal Antibody Therapy
  • Track 5-2Monoclonal and Polyclonal antibodies
  • Track 5-3Monoclonal Antibody Therapy for Cancer
  • Track 5-4Monoclonal Antibodies Applications
  • Track 5-5Hybridoma Technology and Monoclonal Antibody Preparation
  • Track 5-6 Antibody Research in Agriculture, Aquaculture, Veterinary and Food Sciences
  • Track 5-7Antibody Technology in New Protein Discovery

Antibodies are used extensively as diagnostic tools in many different formats. The term applied for antibody based diagnostic tests is “immunoassay”. Antibody-based immunoassays are the most commonly used confirmatory diagnostic assays and is the fastest growing technologies for the analysis of biomolecules. Trends in antibody based diagnosis show advances in assay specificity, detection technologies and sensitivity. Sensitivity and specificity is ensured depending on whether or not the antigen to be quantified competes with labeled antigen for a limited number of antibody binding sites. Monoclonal antibodies are now widely used in all areas of biological and medical research as well as in clinical diagnostic tests and in therapy. This review concentrates on the clinical use of antibodies in therapy particularly with regard to the properties of the antibodies which seem most relevant to their usefulness. In-vitro tests using human effector systems and in-vivo animal models have demonstrated the importance of the antibody isotype and valency for antigen as well as the specificity of binding.

  • Track 6-1Novel Antibodies in Medical Treatment and Diagnosis
  • Track 6-2Antibodies for Immuno histochemistry and Immunofluorescence
  • Track 6-3Antibody for Western Blot Analyses, ELISA and ELISPOT Techniques

Antibody therapies are the most successful immunotherapy, treating a wide range of cancers. Antibodies are proteins produced by the immune system that bind to a target antigen on the cell surface. In normal physiology the immune system uses them to fight pathogens. Each antibody is specific to one or a few proteins. Those that bind to cancer antigens are used to treat cancer. Cell surface receptors are common targets for antibody therapies. Among the most promising approaches to activating therapeutic antitumor immunity is the blockade of immune checkpoints. Immune checkpoints refer to a plethora of inhibitory pathways hardwired into the immune system that are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiological immune responses in peripheral tissues in order to minimize collateral tissue damage. It is now clear that tumors co-opt certain immune-checkpoint pathways as a major mechanism of immune resistance, particularly against T cells that are specific for tumor antigens. Because many of the immune checkpoints are initiated by ligand–receptor interactions, they can be readily blocked by antibodies or modulated by recombinant forms of ligands or receptors. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) antibodies were the first of this class of immunetherapeutics to achieve US Food and Drug Administration (FDA) approval.

  • Track 7-1Combinations of Check-Point Inhibitors
  • Track 7-2In Vivo Discovery of Immunotherapy Targets
  • Track 7-3Immune Suppression and Microenvironment
  • Track 7-4Sequencing or Combination Approaches in Immunotherapy
  • Track 7-5Chimeric Antigen Receptor Re-Directed T Cell Therapy

Biosimilars and biobetters industry is likely to become a lot more dynamic and strategic than we’ve seen with small molecule generics; there will begin to become a premium on flexibility and willingness to take chances in an ever-shifting competitive and regulatory environment. The approval of the first biosimilar in the US is expected to save the healthcare industry and patients $5.7 billion over the next decade. The US biosimilars market is expected to reach $2 billion by 2018 and with the first biosimilar approved recently in America, this is an exciting time for the biosimilar field with approval in the US expected to increase during the next ten years. The regulatory landscape is evolving rapidly so it is important to understand the developments in the biosimilar guideline framework and the cohesion in legislation between the US and Europe. Key factors driving market growth include patent expiries of key biological drugs, cost containment measures from governments, aging population, and supporting legislations. The recent establishment of regulatory guidelines for biosimilars in the US is expected to add further momentum to the growth of the global biosimilars market. Increasing pressure from governments and insurers for greater biologic competition, there exists an incredible opportunity for biosimilar producers to capitalise on what is set to become the fastest growing sector of the pharmaceutical industry. 

  • Track 8-1Biosimilars and Non-Originator Biologics
  • Track 8-2Biosimilar Regime
  • Track 8-3Use of Autologous IL-1ra and Other Cytokines in Orthopedics
  • Track 8-4 Technological Platform for Innovative and Biosimilar Antibodies
  • Track 8-5Biosimilars and Non-Originator Biologics
  • Track 8-6Novel Cell-Based Bioassays for Analysis of mAb Fc Effector and Immune Checkpoint

Conventional anticancer therapeutics often suffer from lack of specificity, resulting in toxicities to normal healthy tissues and poor therapeutic index. Antibody-drug conjugates (ADCs) constitute a therapeutic modality in which a cytotoxic agent is chemically linked to an antibody (Ab) that recognizes a tumor-associated antigen. The basic strategy underlying ADC technology is to combine the target selectivity of mAbs with the potency of cytotoxic agents, such as certain natural products and synthetic molecules, with the goal of generating therapeutic drugs that are highly efficacious but also safe. The ADC platform currently includes a growing repertoire of cytotoxic payloads, linker technologies and conjugation methods. Two ADCs have recently received FDA approval and more than 30 are in clinical development. This meeting aims to highlight advances in ADC research, clinical development and regulatory perspectives.

  • Track 9-1Challenges and New Opportunities with Antibody and Protein Drugs
  • Track 9-2Novel Antibody and Biologic Drug Targets
  • Track 9-3Innovative Antibody drugs in Clinical Trail and Development
  • Track 9-4Antibody-drug Conjugate (ADC) Discovery and Development
  • Track 9-5Bispecific and Multispecific antibody discovery and development

The outlook for therapeutic antibodies is very promising. This meeting will highlight current trends in development including identifying and validating novel targets, improving drug-like properties, employing immunotherapy approaches and advancing novel constructs. This program has consistently recruited top thought leaders in the field to review the status of myriad innovative antibodies and key ideas for advancing them towards the clinic. The immune system has evolved to fight infection, and the response to microbial infection involves the activation of a complex network in which numerous cell types, soluble factors and adhesion molecules of the host immune system participate. It is therefore not possible to produce a good textbook in immunology without any reference to infection or infectious agents. Immunology, Infection, and Immunity has been produced with this in mind, and the Editors have clearly done this with an appreciation of the immune system as a defence system.          
 

  • Track 10-1Mastering Immunogenicity: Tools and Technologies
  • Track 10-2Validation of Cell Based Antibody Neutralization Assays
  • Track 10-3Strategies to Assess Immunogenicity
  • Track 10-4Case Studies: Pre-Clinical Immunogenicity Assessment
  • Track 10-5Lymphocytes: Research and Novel Strategies

Anticancer antibodies  has created great interest in antibody-based therapeutics for hematopoietic malignant neoplasms and solid tumors. Given the likelihood of lower toxic effects of antibodies that target tumor cells and have limited impact on nonmalignant bystander organs vs small molecules, the potential increased efficacy by conjugation to radioisotopes and other cellular toxins, and the ability to characterize the target with clinical laboratory diagnostics to improve the drug's clinical performance, current and future antibody therapeutics are likely to find substantial roles alone and in combination therapeutic strategies for treating patients with cancer. Therapeutic antibodies have become a major strategy in clinical oncology owing to their ability to bind specifically to primary and metastatic cancer cells with high affinity and create antitumor effects by complement-mediated cytolysis and antibody-dependent, cell-mediated cytotoxicity (naked antibodies) or by the focused delivery of radiation or cellular toxins (conjugated antibodies).

  • Track 11-1Antibodies in Treatment of Cancer
  • Track 11-2Characterizing and clinical use of Circulating Tumor Cells (CTCS)
  • Track 11-3 Advances in tumor modeling, cancer drug discovery and development
  • Track 11-4Translational approaches in cancer immunotherapy development
  • Track 11-5 Innovative in vitro and in vivo modeling

Cancer immunotherapy—treatments that harness and enhance the innate powers of the immune system to fight cancer—represents the most promising new cancer treatment approach since the development of the first chemotherapies in the late 1940s. Because of the immune system’s extraordinary power, its capacity for memory, its exquisite specificity, and its central and universal role in human biology, these treatments have the potential to achieve complete, long-lasting remissions and cancer cures, with few or no side effects, and for any cancer patient, regardless of their cancer type. Immunotherapy is treatment that uses your body's own immune system to help fight cancer. These treatment modalities are all based on destroying cancer cells by burning them (irradiation), poisoning them (chemotherapy) or removing them (surgery). While they can effectively kill or remove cancer cells, the use of these treatments often is limited because large numbers of healthy cells also tend to be destroyed. This often results in extreme morbidity and/or disfigurement of the patients treated with them.

  • Track 12-1Evolving Concepts in Cancer Immunology
  • Track 12-2Anti-tumor activity of immunomodulatory antibodies
  • Track 12-3Tumor Antigens for Targeting: Insights from Genomics
  • Track 12-4 Impact of the immunogenic landscape of cancers on immunotherapy
  • Track 12-5 Cancer neo-antigens

The first monoclonal antibodies were typically made entirely from mouse cells. One problem with this is that the human immune system will see these antibodies as foreign (because they’re from a different species) and will mount a response against them. In the short term, this can sometimes cause an immune response. In the long term, it means that the antibodies may only work the first time they are given; after that, the body’s immune system is primed to destroy them before they can provide treatment. This study presents a technology that generates stable, soluble, ultra-humanized antibodies via single-step CDR redundancy minimization. Lead clones demonstrated high stability, with affinity and specificity equivalent to, or better than, the parental immunoglobulin. This significantly lowered non-human sequence content, minimized t- and b-cell epitope risk in the final molecules and provided a heat map for the essential non-human CDR residue content of antibodies from disparate sources. Antibody humanization uses multiple sequence segments derived from variable (V) regions of unrelated human antibodies, unlike other technologies that typically use a single human V region framework as acceptors for complementarity determining regions (CDRs) from starting antibodies (typically rodent). Through careful selection of human sequence segments and the application of in silico tools, CD4+ T cell epitopes are avoided so the risk of immunogenicity is reduced compared to standard humanized antibodies whilst antibody affinity and specificity is maintained. Immunogenicity assessment technology is used to confirm T cell epitopes have been removed.

  • Track 13-1Rapid Humanization and Affinity Improvement of a Murine Antibody
  • Track 13-2IMGT Databases and Tools for Antibody Engineering and Humanization
  • Track 13-3Immunogenicity Assessment Strategies to Support the Development of Biological Therapeutics
  • Track 13-4Therapeutic Antibody Discovery and Development Using Humanized RabMAbs
  • Track 13-5Humanized Antibodies and Their Therapeutic Value
  • Track 13-6Non-human Primate Immune Libraries Combined with Germline Humanization
  • Track 13-7A Novel Fully Human Monoclonal Antibody Platform Using Transgenic Rats

The development of cancer therapies is increasingly dependent on our understanding of tumor biology, and biomarkers—especially predictive biomarkers—are crucial tools in the field of personalized medicine and health economics, in particular, as they enable definition of the populations of patients who are most likely to benefit from targeted therapies. More-effective patient selection than is possible at present is mandatory to improve the success rate of new therapies, which are sometimes prohibitively expensive, and thereby increase their cost–utility; thus, delineating reliable predictive biomarkers is essential if we are to achieve this objective. One commonly used definition of a biomarker is a measurable indicator that is used to distinguish precisely, reproducibly and objectively either a normal biological state from a pathological state, or the response to a specific therapeutic intervention. In fact, biomarkers are used for numerous purposes: to predict survival (prognostic biomarkers); to assess drug safety and evaluate target engagement and the immediate consequence on biological processes (pharmacodynamics biomarkers), to identify patients who are more likely to benefit from a treatment (predictive biomarkers; more generally termed companion biomarkers when associated with a specific therapeutic agent); to predict outcome given the response to therapy (surrogate biomarkers); and to monitor disease progression or therapeutic efficacy (monitoring biomarkers). Identification and widespread use of biomarkers will help ensure that patients receive the best possible therapeutic strategies, thereby avoiding unnecessary treatments and associated toxicities, and eventually reducing total health costs.

  • Track 14-1Turning an Active Compound into a Personalized Medicine
  • Track 14-2Evaluation of Biomarker Performance in the Real World
  • Track 14-3Predicting Benefit to Therapy: Biomarkers and Molecular Profiles in Oncology Drug Development
  • Track 14-4Identification of Fluid Biomarkers of Treatment
  • Track 14-5Surrogate endpoints: utilising biomarkers in clinical trials

Biopharmaceuticals is one of the fastest growing segments in the pharmaceutical industry. They have a vital use in the treatment of chronic diseases and also result in high profit margins for the drug developers. There are several therapeutic areas for which biopharmaceuticals are being investigated; these include oncology, metabolic disorders, viral infections, genetic disorders and immunological disorders

  • Track 15-1Formulation and delivery issues for monoclonal antibody therapeutics
  • Track 15-2Microneedles for drug and vaccine delivery
  • Track 15-3Biopharmaceutical formulations for pre-filled delivery devices
  • Track 15-4Nanotechnological advances for the delivery of CNS therapeutics
  • Track 15-5Biotherapeutics in Orthopaedic Medicine

BioTherapeutics is focused on developing innovative antibody-based cancer treatments, based on a range of proprietary technologies. These target a number of oncology indications, with a particular focus on cancers with limited treatment options. These include a mixture of solid and liquid malignancies, such as acute myeloid leukemia and breast, ovarian and lung cancers. Monoclonal antibodies have emerged as a class of novel oncology therapeutics. 

  • Track 16-1Advances in bispecific biotherapeutics for the treatment of cancer
  • Track 16-2Antibody-drug conjugates for cancer therapy
  • Track 16-3Angiogenesis inhibitor antibodies
  • Track 16-4Biotherapeutic approaches to target cancer stem cells

The modular structure of antibodies has enabled the customization and engineering of high affinity binders in a variety of ways. Before discussing the technologies developed for the design and discovery of antibody fragments. Antibody engineering technologies have surpassed many of the challenges imposed by the selection of antibodies using murine cell lines (i.e., hybridoma technology), eliminating the need for humanization by enabling the production of fully human antibodies in vitro or in other engineered animal models. 

  • Track 17-1Antibodies Applications and New Developments
  • Track 17-2Protein & Antibody Engineering
  • Track 17-3Antibodies And Vaccines Against Infectious Diseases
  • Track 17-4Target Discovery And Validation

Antibody conjugates are a diverse class of therapeutics consisting of a cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surface target expressed by tumor cells. The notion that antibodies directed toward targets on the surface of malignant cells could be used for drug delivery is not new.

  • Track 18-1Antibody-Drug Conjugates Design And Development
  • Track 18-2Bispecific antibody conjugates in therapeutics
  • Track 18-3Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
  • Track 18-4New Developments in Antibody-Drug Conjugates

Next-generation sequencing (NGS) provides a quantitative approach to measuring the diversity and distribution of antibody libraries. It will introduce and enable researchers on how to design, analyze, and perform antibody NGS studies and how these can be applied for discovery and engineering of monoclonal antibodies from both synthetic and immune libraries. 

  • Track 19-1Nanoengineering Strategies for Antibody- Nanoparticle Conjugates
  • Track 19-2Next-Generation Sequencing Of Antibody Libraries
  • Track 19-3Biologics for Autoimmune Diseases
  • Track 19-4Biologics and Vaccines for Infectious Diseases
  • Track 19-5NGS Clinical Applications & Diagnostics

Therapeutic proteins and monoclonal antibodies (MAb) have transformed biotechnology and the pharmaceutical industry. Together they form the largest part of the rapidly growing biologics drug market. Protein-based drugs include blood factors, thrombolytic agents, hormones, hematopoietic growth factors, interferons, interleukins, tumor necrosis factor, and therapeutic enzymes. 

  • Track 20-1Protein Particulate Detection Issues in Biotherapeutics Development
  • Track 20-2Analytical Development For Emerging Biotherapeutics
  • Track 20-3Automation And Emerging Analytical Methods
  • Track 20-4Bioanalytical Considerations Of Multi-Domain Biotherapeutics: Preclinical And Clinical Development

New biotherapeutics formats are flooding the discovery and development pipelines and with this comes an increasing need for better and faster characterization tools and strategies, and improved biomolecular and biophysical assays for the new biotherapeutics. 

  • Track 21-1Assay development
  • Track 21-2High throughput analytical development
  • Track 21-3Early stage bioassay development
  • Track 21-4Analytical development for novel biotherapeutics